Interstitial Lung Disease in Systemic Sclerosis

 

 Buy Article Permissions and Reprints

Abstract

Despite many unanswered questions regarding the pathogenesis of interstitial lung disease in systemic sclerosis (SSc-ILD) and the lack of accurate epidemiological risk factors, there have been major advances in the identification and prognostic evaluation of SSc-ILD. The evaluation of disease severity is a multidisciplinary exercise, requiring the integration of pulmonary function tests, high-resolution computed tomography data, and symptomatic severity and these factors all need to be considered in the detection of disease progression. Except in a minority of patients with reversible inflammatory disease, the primary goal of treatment is the prevention of disease progression. Current treatment regimens are centered on immunosuppressive therapy with controlled treatment data largely confined to the use of cyclophosphamide. The results of two controlled trials indicate that cyclophosphamide therapy is appropriate in SSc-ILD patients with extensive fibrotic lung involvement. There is a need to broaden therapeutic approaches with the exploration of rituximab (based on recent pilot data) and antifibrotic agents, shown to have treatment effects in other fibrotic interstitial lung diseases. However, it is also important to avoid the overtreatment of SSc-ILD patients with limited nonprogressive lung involvement. In that setting, an initial policy of nonintervention but meticulous observation (“masterful inactivity with cat-like observation”) is often warranted.

• References

• 1 Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37 (4) 223-235
  CrossrefPubMedGoogle Scholar
• 2 American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165 (2) 277-304
  CrossrefPubMedGoogle Scholar
• 3 Tyndall AJ, Bannert B, Vonk M , et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69 (10) 1809-1815
  CrossrefPubMedGoogle Scholar
• 4 Steen VD, Conte C, Owens GR, Medsger Jr TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37 (9) 1283-1289
  CrossrefPubMedGoogle Scholar
• 5 Mayes MD, Lacey Jr JV, Beebe-Dimmer J , et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48 (8) 2246-2255
  CrossrefPubMedGoogle Scholar
• 6 Reveille JD. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep 2003; 5 (2) 160-167
  CrossrefPubMedGoogle Scholar
• 7 D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46 (3) 428-440
  CrossrefPubMedGoogle Scholar
• 8 Bouros D, Wells AU, Nicholson AG , et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165 (12) 1581-1586
  CrossrefPubMedGoogle Scholar
• 9 Launay D, Remy-Jardin M, Michon-Pasturel U , et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006; 33 (9) 1789-1801
  PubMedGoogle Scholar
• 10 De Santis M, Bosello S, La Torre G , et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res 2005; 6: 96
  CrossrefPubMedGoogle Scholar
• 11 Desai SR, Veeraraghavan S, Hansell DM , et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004; 232 (2) 560-567
  CrossrefPubMedGoogle Scholar
• 12 Wells AU, Cullinan P, Hansell DM , et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994; 149 (6) 1583-1590
  CrossrefPubMedGoogle Scholar
• 13 Daniil ZD, Gilchrist FC, Nicholson AG , et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160 (3) 899-905
  CrossrefPubMedGoogle Scholar
• 14 Kocheril SV, Appleton BE, Somers EC , et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 2005; 53 (4) 549-557
  CrossrefPubMedGoogle Scholar
• 15 Tashkin DP, Elashoff R, Clements PJ , et al; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354 (25) 2655-2666
  CrossrefPubMedGoogle Scholar
• 16 Goh NS, Desai SR, Veeraraghavan S , et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177 (11) 1248-1254
  CrossrefPubMedGoogle Scholar
• 17 Walker UA, Tyndall A, Czirják L , et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66 (6) 754-763
  CrossrefPubMedGoogle Scholar
• 18 Briggs DC, Vaughan RW, Welsh KI, Myers A, duBois RM, Black CM. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991; 338 (8768) 661-662
  CrossrefPubMedGoogle Scholar
• 19 Gilchrist FC, Bunn C, Foley PJ , et al. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun 2001; 2 (2) 76-81
  CrossrefPubMedGoogle Scholar
• 20 Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000; 43 (5) 1074-1084
  CrossrefPubMedGoogle Scholar
• 21 Hu PQ, Fertig N, Medsger Jr TA, Wright TM. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003; 48 (5) 1363-1373
  CrossrefPubMedGoogle Scholar
• 22 Reveille JD, Solomon DH ; American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003; 49 (3) 399-412
  CrossrefPubMedGoogle Scholar
• 23 Feghali-Bostwick C, Medsger Jr TA, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48 (7) 1956-1963
  CrossrefPubMedGoogle Scholar
• 24 Zhou X, Tan FK, Wang N , et al. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 2003; 48 (9) 2585-2592
  CrossrefPubMedGoogle Scholar
• 25 Allanore Y, Dieude P, Boileau C. Genetic background of systemic sclerosis: autoimmune genes take centre stage. Rheumatology (Oxford) 2010; 49 (2) 203-210
  CrossrefPubMedGoogle Scholar
• 26 Kawaguchi Y, Tochimoto A, Ichikawa N , et al. Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population. Arthritis Rheum 2003; 48 (1) 186-192
  CrossrefPubMedGoogle Scholar
• 27 Beretta L, Bertolotti F, Cappiello F , et al. Interleukin-1 gene complex polymorphisms in systemic sclerosis patients with severe restrictive lung physiology. Hum Immunol 2007; 68 (7) 603-609
  CrossrefPubMedGoogle Scholar
• 28 Sumita Y, Sugiura T, Kawaguchi Y , et al. Genetic polymorphisms in the surfactant proteins in systemic sclerosis in Japanese: T/T genotype at 1580 C/T (Thr131Ile) in the SP-B gene reduces the risk of interstitial lung disease. Rheumatology (Oxford) 2008; 47 (3) 289-291
  PubMedGoogle Scholar
• 29 Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 1-100
  PubMedGoogle Scholar
• 30 Wells AU, King AD, Rubens MB, Cramer D, du Bois RM, Hansell DM. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 1997; 155 (4) 1367-1375
  CrossrefPubMedGoogle Scholar
• 31 Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131 (3) 657-663
  CrossrefPubMedGoogle Scholar
• 32 Steen VD, Graham G, Conte C, Owens G, Medsger Jr TA. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35 (7) 765-770
  CrossrefPubMedGoogle Scholar
• 33 Hughes JMB, Pride NB. Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components. Am J Respir Crit Care Med 2012; 186 (2) 132-139
  CrossrefPubMedGoogle Scholar
• 34 Schurawitzki H, Stiglbauer R, Graninger W , et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 1990; 176 (3) 755-759
  CrossrefPubMedGoogle Scholar
• 35 Wells AU, Rubens MB, du Bois RM, Hansell DM. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. AJR Am J Roentgenol 1993; 161 (6) 1159-1165
  CrossrefPubMedGoogle Scholar
• 36 Shah RM, Jimenez S, Wechsler R. Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis. J Thorac Imaging 2007; 22 (2) 120-124
  CrossrefPubMedGoogle Scholar
• 37 Wells AU. Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear. Thorax 2013; 68 (4) 309-310
  CrossrefPubMedGoogle Scholar
• 38 Ohnishi H, Yokoyama A, Kondo K , et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002; 165 (3) 378-381
  CrossrefPubMedGoogle Scholar
• 39 Hasegawa M, Fujimoto M, Hamaguchi Y , et al. Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis. J Rheumatol 2011; 38 (5) 877-884
  CrossrefPubMedGoogle Scholar
• 40 Bonella F, Volpe A, Caramaschi P , et al. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28 (1) 27-33
  PubMedGoogle Scholar
• 41 De Lauretis A, Sestini P, Pantelidis P , et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013; 40 (4) 435-446
  CrossrefPubMedGoogle Scholar
• 42 Goh NS, Desai SR, Anagnostopoulos C , et al. Increased epithelial permeability in pulmonary fibrosis in relation to disease progression. Eur Respir J 2011; 38 (1) 184-190
  CrossrefPubMedGoogle Scholar
• 43 Goh NS, Veeraraghavan S, Desai SR , et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56 (6) 2005-2012
  CrossrefPubMedGoogle Scholar
• 44 Strange C, Bolster MB, Roth MD , et al; Scleroderma Lung Study Research Group. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177 (1) 91-98
  CrossrefPubMedGoogle Scholar
• 45 Hoyles RK, Ellis RW, Wellsbury J , et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54 (12) 3962-3970
  CrossrefPubMedGoogle Scholar
• 46 Seibold JR, Denton CP, Furst DE , et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010; 62 (7) 2101-2108
  PubMedGoogle Scholar
• 47 Kowal-Bielecka O, Landewé R, Avouac J , et al; EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68 (5) 620-628
  CrossrefPubMedGoogle Scholar
• 48 Tashkin DP, Elashoff R, Clements PJ , et al; Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176 (10) 1026-1034
  CrossrefPubMedGoogle Scholar
• 49 White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132 (12) 947-954
  PubMedGoogle Scholar
• 50 Fischer A, Brown KK, Du Bois RM , et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40 (5) 640-646
  CrossrefPubMedGoogle Scholar
• 51 Steen VD, Medsger Jr TA. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41 (9) 1613-1619
  CrossrefPubMedGoogle Scholar
• 52 DeMarco PJ, Weisman MH, Seibold JR , et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46 (11) 2983-2989
  CrossrefPubMedGoogle Scholar
• 53 Demedts M, Behr J, Buhl R , et al; IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353 (21) 2229-2242
  CrossrefPubMedGoogle Scholar
• 54 Noble PW, Albera C, Bradford WZ , et al; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377 (9779) 1760-1769
  CrossrefPubMedGoogle Scholar
• 55 Burt RK, Shah SJ, Dill K , et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378 (9790) 498-506
  CrossrefPubMedGoogle Scholar
• 56 Nash RA, McSweeney PA, Crofford LJ , et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007; 110 (4) 1388-1396
  CrossrefPubMedGoogle Scholar
• 57 Daoussis D, Liossis SN, Tsamandas AC , et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010; 49 (2) 271-280
  CrossrefPubMedGoogle Scholar
• 58 Daoussis D, Liossis SN, Tsamandas AC , et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012; 30 (2, Suppl 71): S17-S22
  PubMedGoogle Scholar